Analysis of Antidiabetic Drug Canagliflozin and Related Isomeric Impurities Using the ACQUITY UPC2 System for Method Screening and Scale Up to Prep SFC System

Importance of the Topic

Effective separation of isomeric impurities in antidiabetic drug canagliflozin is essential to ensure product purity, potency, and regulatory compliance. Impurities in beta and alpha sugar moieties can impact API safety and therapeutic performance. Rapid and selective analytical methods support quality control and accelerate generic drug development.

Study Objectives and Overview

This study aimed to develop and evaluate a supercritical fluid chromatography method using the ACQUITY UPC2 system to separate canagliflozin and related isomeric impurities. The approach included method screening, resolution assessment, and scale up to preparative SFC for potential isolation of isomers.

Methodology

The analytical method employed a UPC2 Trefoil AMY1 column with compressed carbon dioxide and a methanol/isopropanol modifier containing trifluoroacetic acid. A gradient from 5 to 50 % organic modifier over 8 minutes and an ABPR pressure of 2000 psi yielded separation in an 11 minute runtime. Detection was performed by UV at 290 nm and orthogonal mass spectrometry in ESI positive mode.

Instrumentation Used

• ACQUITY UPC2 system with PDA detector
• ACQUITY UPC2 Trefoil AMY1 column (3 mm × 150 mm, 2.5 μm)
• ACQUITY SQ Detector mass spectrometer
• Empower 3 software for data acquisition

Results and Discussion

The UPC2 method achieved baseline resolution of beta isomer, an unknown isomeric impurity, and alpha isomer with retention times of approximately 6.6, 7.2, and 8.4 minutes. Resolution factors exceeded USP requirements (5.10, 2.47, 6.01). The shorter runtime contrasted with a 65 minute reversed-phase approach and reduced organic solvent usage. Mass detection confirmed identity via the sodium adduct at m/z 467. Reproducibility was demonstrated with %RSD < 1 % for retention times and areas across replicate injections.

Practical Applications and Benefits

The method delivers faster analysis, improved selectivity, and greener operation versus conventional reversed-phase chromatography. It supports high-throughput screening in research, robust QC assays in manufacturing, and enables scale up to preparative SFC for isolation of isomeric impurities.

Future Trends and Potential Applications

Advances in supercritical fluid chromatography will expand chiral separations, further reduce solvent consumption, and integrate with automated preparative workflows. UPC2 techniques may be extended to other complex APIs and impurity profiling, enhancing efficiency in drug development and regulatory submissions.

Conclusion

The ACQUITY UPC2 method offers a rapid, selective, and environmentally friendly solution for analyzing canagliflozin and related isomeric impurities. Its strong resolution, reproducibility, and scalability make it a valuable tool for pharmaceutical quality control and preparative purification.

References

1. Ahuja S, Alsante K. Handbook of Isolation and Characterization of Impurities in Pharmaceutical Compounds. Elsevier, 2003.
2. De Klerck K et al. Supercritical Fluid Chromatography for the Enantioseparation of Pharmaceuticals. J Pharm Biomed Anal. 2012;doi:10.1016/j.jpba.2012.01.021.
3. Kuriyama C et al. Effect of Canagliflozin on Renal Glucose Reabsorption. J Pharmacol Exp Ther. 2014;351(2):423–31.
4. Shawaqfeh MS et al. Adverse Drug Events Related to Canagliflozin: A Meta-Analysis. Adv Pharmacoepidemiol Drug Saf. 2015;4:196.
5. Tarafder A et al. Chiral Scale-Up and Purification Using UPC2 and Prep SFC. J Chromatogr A. 2012;1258:136–151.
6. Runco J. Demonstrating Chiral Scale-Up and Purification Using UPC2 and Prep 80q SFC Systems. Waters Application Note 2015.